MarketPulse

Cushing's syndrome

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Corcept Faces Class Action Over Relacorilant Misstatement; Investor Deadline Looms

Corcept Therapeutics faces class action lawsuit alleging investor deception over failed relacorilant drug trial. Stock plunged 50.4% after FDA rejection.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Corcept Therapeutics Hit With Class Action Over Misleading FDA Drug Claims

Corcept Therapeutics faces class action lawsuit for allegedly misleading investors about relacorilant's FDA prospects. Stock plummeted 50.4% after FDA rejection; investors from October 2024-December 2025 eligible to sue.
CORTsecurities fraudclass action lawsuit
The Motley FoolThe Motley Fool··Eric Volkman

Corcept Therapeutics Surges 9% on FDA Approval of Cancer Drug Lifyorli

Corcept Therapeutics stock surged 9% following FDA approval of cancer drug Lifyorli. An analyst upgraded the stock to hold amid concerns about existing Korlym franchise performance.
CORTFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Portnoy Law Firm Files Class Action Against Corcept Therapeutics Over FDA Drug Rejection

Portnoy Law Firm sues Corcept Therapeutics over alleged misrepresentations about drug candidate relacorilant, following FDA rejection that caused stock to plummet 50%.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Corcept Therapeutics Faces Class Action Over Relacorilant Clinical Evidence Claims

Corcept Therapeutics faces class action lawsuit for allegedly misleading statements about relacorilant's clinical evidence. FDA rejected the drug application, causing stock to plummet 50%.
CORTclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Corcept Therapeutics Faces Class Action Over Relacorilant FDA Rejection

Corcept Therapeutics faces class action lawsuit over alleged misrepresentation regarding relacorilant drug. FDA rejected the application citing insufficient efficacy data; stock plummeted over 50%.
CORTsecurities fraudclass action lawsuit